Thomas Jonassen
Chief Tech/Sci/R&D Officer at SYNACT PHARMA AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kristian Helin | M | - |
University of Copenhagen
| - |
| Jeppe Øvlesen | M | 62 |
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | 8 years |
| Niels Kærgård | M | 81 |
University of Copenhagen
| 16 years |
| Jesper Zeuthen | M | - |
University of Copenhagen
| - |
| Jacob Rosenberg | M | 59 |
University of Copenhagen
| 21 years |
| Lykke Friis | M | 54 |
University of Copenhagen
| - |
| Jens Borum | M | 70 |
University of Copenhagen
| - |
| Jakob Bo Thomasen | M | 62 |
University of Copenhagen
| - |
| Hans Siggaard Jensen | M | - |
University of Copenhagen
| - |
| Peter Boman Samuelsen | M | - |
University of Copenhagen
| - |
| James Knight | M | - | 3 years | |
| Karen Laigaard | F | 58 |
University of Copenhagen
| - |
| Lars Søren Rasmussen | M | 65 |
University of Copenhagen
| - |
| Gunhild Waldemar | M | 67 |
University of Copenhagen
| - |
| Lars Henrik Fugger | M | 64 |
University of Copenhagen
| 15 years |
| David Woldbye | M | 61 |
University of Copenhagen
| - |
| Magnus Fontes | M | 61 |
University of Copenhagen
| - |
| Jan Stenvang | M | - |
University of Copenhagen
| 11 years |
| Kristine Færch | F | 48 |
University of Copenhagen
| - |
| Steven Goldman | M | 66 |
University of Copenhagen
| 10 years |
| Thomas Bjarnsholt | M | - |
University of Copenhagen
| - |
| Jan Hesthaven | M | - |
University of Copenhagen
| - |
| Mikkel Bogh | M | - |
University of Copenhagen
| - |
| Karsten Kristiansen | M | - |
University of Copenhagen
| - |
| Niels Borregaard | M | 73 |
University of Copenhagen
| 26 years |
| Thomas Boesen | M | - | 3 years | |
| Ole Thastrup | M | 71 |
University of Copenhagen
| - |
| Boel Flodgren | M | 82 |
University of Copenhagen
| - |
| Peter Buhl Jensen | M | 69 |
University of Copenhagen
| - |
| Henrik Stage | M | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
| Björn Westberg | M | 62 | 1 years | |
| Kirsten Drejer | M | 68 |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
| Povl Krogsgaard-Larsen | M | 83 |
University of Copenhagen
| - |
| Anders Kronborg | M | 60 |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | 1 years |
| Carsten Gomard | M | 58 |
University of Copenhagen
| - |
| Thomas Feldthus | M | 64 |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
| Agnete Raaschou-Nielsen | M | 66 |
University of Copenhagen
| - |
| Sven M. Jacobson | M | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | - |
| Thue Walter Schwartz | M | - |
University of Copenhagen
| - |
| Peter Gæmelke | M | 69 |
University of Copenhagen
| - |
| Lars Åke Alvar Lidgren | M | 81 |
University of Copenhagen
| - |
| Steen Meier Rønborg | M | 70 |
University of Copenhagen
| - |
| Per Stahl Skov | M | 78 |
University of Copenhagen
| 43 years |
| Ellen Holm Nielsen | F | - |
University of Copenhagen
| - |
| Nils Aage Brünner | M | 72 |
University of Copenhagen
| 22 years |
| Kirsten Harting | M | - | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| Denmark | 42 | 91.30% |
| Sweden | 4 | 8.70% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas Jonassen
- Personal Network